AbbVie Inc. $ABBV Shares Sold by Investment House LLC

Key Points

• Investment House LLC cut its AbbVie position by 50.2% in the third quarter, selling 23,074 shares and retaining 22,864 shares worth approximately $5.98 million. Institutional investors collectively own 70.23% of the company.
• AbbVie reported quarterly revenue of $16.99 billion and adjusted EPS of $3.65, exceeding analyst expectations, while revenue rose 10.2% year over year. The company declared a quarterly dividend of $1.73, equivalent to a 2.4% annual yield.
• AbbVie’s lutikizumab Phase 3 trial met its primary and secondary endpoints, but analysts questioned the treatment’s commercial competitiveness because efficacy reportedly lagged some benchmarks. Analysts remain broadly positive, with a “Moderate Buy” consensus rating and several firms raising price targets.

Investment House LLC decreased its position in AbbVie Inc. (NYSE:ABBV - Free Report) by 50.2% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 22,864 shares of the company's stock after selling 23,074 shares during the period. Investment House LLC's holdings in AbbVie were worth $5,981,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the company. State Street Corp increased its holdings in shares of AbbVie by 1.7% in the second quarter. State Street Corp now owns 82,596,748 shares of the company's stock worth $20,784,646,000 after acquiring an additional 1,379,232 shares in the last quarter. Corient Private Wealth LP bought a new position in shares of AbbVie during the 2nd quarter valued at about $559,736,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of AbbVie by 0.7% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,267,697 shares of the company's stock valued at $3,590,323,000 after purchasing an additional 106,091 shares in the last quarter. Legal & General Group Plc acquired a new position in shares of AbbVie in the 2nd quarter valued at approximately $2,905,952,000. Finally, Deutsche Bank AG grew its position in shares of AbbVie by 13.0% in the 2nd quarter. Deutsche Bank AG now owns 10,772,949 shares of the company's stock valued at $2,710,905,000 after purchasing an additional 1,241,587 shares during the period. Institutional investors own 70.23% of the company's stock.

AbbVie Stock Down 0.1%

Shares of ABBV opened at $284.59 on Friday. The stock has a market capitalization of $502.80 billion, a P/E ratio of 80.39, a P/E/G ratio of 1.30 and a beta of 0.24. AbbVie Inc. has a twelve month low of $190.75 and a twelve month high of $291.40. The company has a 50 day moving average of $265.60 and a 200-day moving average of $241.46.

AbbVie (NYSE:ABBV - Get Free Report) last announced its quarterly earnings data on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping analysts' consensus estimates of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. During the same quarter in the previous year, the firm posted $2.97 earnings per share. The firm's revenue for the quarter was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, sell-side analysts anticipate that AbbVie Inc. will post 13.94 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 2.4%. The ex-dividend date is Thursday, October 15th. AbbVie's payout ratio is presently 195.48%.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Lutikizumab met its Phase 3 INTREPID trial objectives. AbbVie reported that the experimental treatment for moderate-to-severe hidradenitis suppurativa achieved its primary HiSCR75 endpoint and eight ranked secondary endpoints, including reduced skin pain and fewer disease flares. The drug was generally well tolerated, with no new safety concerns. AbbVie INTREPID Phase 3 results
• Positive Sentiment: Investors continue to see potential in AbbVie’s broader immunology pipeline. Phase 2a results for a possible Skyrizi successor in Crohn’s disease and a promising eczema candidate could help support growth as AbbVie prepares for future patent expirations. Great News for AbbVie Stock Investors
• Neutral Sentiment: The INTREPID results were positive but commercially ambiguous. Although lutikizumab reduced abscess burden and met prespecified endpoints, the magnitude of benefit reportedly fell short of analyst benchmarks. That raises questions about the drug’s competitive positioning and potential sales opportunity, despite the successful trial. AbbVie skin disease drug Phase 3 results
• Negative Sentiment: Analysts characterized the efficacy as underwhelming. Lutikizumab beat placebo by roughly eight percentage points on its main measure, but the result lagged some efficacy benchmarks. Shares of rival MoonLake rose on expectations that its competing hidradenitis suppurativa therapy may remain better positioned. MoonLake reaction to AbbVie trial data
• Negative Sentiment: AbbVie halted an early-stage liver-cancer combination study. The discontinued Phase 1b trial removes one development program from the oncology pipeline, although its financial impact is likely limited compared with the company’s late-stage immunology portfolio. AbbVie liver cancer trial update

Analysts Set New Price Targets

ABBV has been the subject of a number of research reports. HSBC increased their target price on AbbVie from $300.00 to $315.00 and gave the stock a "buy" rating in a research note on Thursday, September 10th. Bank of America reiterated a "buy" rating on shares of AbbVie in a report on Tuesday, September 8th. Wells Fargo & Company increased their price objective on shares of AbbVie from $295.00 to $300.00 and gave the stock an "overweight" rating in a research report on Monday, August 17th. UBS Group increased their price objective on shares of AbbVie from $260.00 to $275.00 and gave the stock a "neutral" rating in a research report on Tuesday, October 6th. Finally, Scotiabank boosted their price objective on shares of AbbVie from $280.00 to $320.00 and gave the company an "outperform" rating in a research report on Tuesday, October 6th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have issued a Hold rating to the company's stock. Based on data from MarketBeat, AbbVie currently has an average rating of "Moderate Buy" and an average price target of $278.07.

Insider Transactions at AbbVie

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the business's stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the sale, the executive vice president directly owned 74,430 shares of the company's stock, valued at $18,607,500. The trade was a 30.53% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders own 0.06% of the company's stock.

About AbbVie

AbbVie Inc NYSE: ABBV is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company's key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.